Compare BridgeBio Pharma Inc (BBIO) vs Moderna, Inc. (MRNA) Price & Performance

BridgeBio Pharma IncTrade

Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Moderna, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Moderna, Inc. trades at $60.83 (market cap $23.88B). The key difference: Moderna, Inc. is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

	BBIO	MRNA
Market Cap	$16.61B	$23.88B
Sector	Health	Health
52-Week High	$90.17	$81.80
52-Week Low	$47.29	$22.36
Enterprise Value	$18.16B	$20.03B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BBIO

BridgeBio beats Q2 estimates, confirms $1B+ 2026 sales goal and plans three product launches by 2027.Seeking Alpha · 20 hours agoBullish View details →

MRNA

New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.Researchandmarkets.Com · 4 days agoNeutral Global influenza vaccine market to grow to $13.32B by 2030, driven by aging population and vaccine innovationsResearchandmarkets.Com · 4 days agoNeutral View details →

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.